Albuvirtide (TFA salt) is primarily used in the treatment of HIV-1 infection. It functions as a fusion inhibitor, preventing the virus from entering human cells by blocking the fusion of the viral envelope with the host cell membrane. This mechanism helps to reduce viral load and slow the progression of the disease. It is often administered as part of combination antiretroviral therapy (ART) to enhance its effectiveness and minimize the risk of drug resistance. Albuvirtide is particularly beneficial for patients who have developed resistance to other antiretroviral drugs, offering an alternative treatment option. Its long-acting formulation allows for less frequent dosing, improving patient adherence to the treatment regimen.